Works by Bubley, Glenn


Results: 27
    1

    A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

    Published in:
    Nature Genetics, 2013, v. 45, n. 7, p. 747, doi. 10.1038/ng.2650
    By:
    • Lunardi, Andrea;
    • Ala, Ugo;
    • Epping, Mirjam T;
    • Salmena, Leonardo;
    • Clohessy, John G;
    • Webster, Kaitlyn A;
    • Wang, Guocan;
    • Mazzucchelli, Roberta;
    • Bianconi, Maristella;
    • Stack, Edward C;
    • Lis, Rosina;
    • Patnaik, Akash;
    • Cantley, Lewis C;
    • Bubley, Glenn;
    • Cordon-Cardo, Carlos;
    • Gerald, William L;
    • Montironi, Rodolfo;
    • Signoretti, Sabina;
    • Loda, Massimo;
    • Nardella, Caterina
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 9, p. 1629, doi. 10.1002/cncr.35170
    By:
    • McKay, Rana R.;
    • Xie, Wanling;
    • Yang, Xiaoyu;
    • Acosta, Andres;
    • Rathkopf, Dana;
    • Laudone, Vincent P.;
    • Bubley, Glenn J.;
    • Einstein, David J.;
    • Chang, Peter;
    • Wagner, Andrew A.;
    • Kane, Christopher J.;
    • Preston, Mark A.;
    • Kilbridge, Kerry;
    • Chang, Steven L.;
    • Choudhury, Atish D.;
    • Pomerantz, Mark M.;
    • Trinh, Quoc‐Dien;
    • Kibel, Adam S.;
    • Taplin, Mary‐Ellen
    Publication type:
    Article
    15

    Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.

    Published in:
    Cancer (0008543X), 2021, v. 127, n. 6, p. 840, doi. 10.1002/cncr.33328
    By:
    • McGregor, Bradley Alexander;
    • Campbell, Matthew T.;
    • Xie, Wanling;
    • Farah, Subrina;
    • Bilen, Mehmet A.;
    • Schmidt, Andrew L.;
    • Sonpavde, Guru P.;
    • Kilbridge, Kerry L.;
    • Choudhury, Atish D.;
    • Mortazavi, Amir;
    • Shah, Amishi Y.;
    • Venkatesan, Aradhana M.;
    • Bubley, Glenn J.;
    • Siefker‐Radtke, Arlene O.;
    • McKay, Rana R.;
    • Choueiri, Toni K.
    Publication type:
    Article
    16
    17
    18

    Reply.

    Published in:
    2009
    By:
    • Liron Pantanowitz;
    • Bohac, Gerry;
    • Cooley, Timothy P.;
    • Aboulafia, David;
    • Bubley, Glenn;
    • Dezube, Bruce J.
    Publication type:
    Letter
    19
    20
    21
    22

    Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation.

    Published in:
    1987
    By:
    • Crumpacker, Clyde;
    • Heagy, Wyrta;
    • Bubley, Glenn;
    • Monroe, James E.;
    • Finberg, Robert;
    • Hussey, Sheila;
    • Schnipper, Lowell;
    • Lucey, Dan;
    • Lee, Tun Hou;
    • McLaine, Mary Fran;
    • Essex, Max;
    • Mulder, Carel;
    • Crumpacker, C;
    • Heagy, W;
    • Bubley, G;
    • Monroe, J E;
    • Finberg, R;
    • Hussey, S;
    • Schnipper, L;
    • Lucey, D
    Publication type:
    journal article
    23
    24
    25
    26
    27